ATSNYSE: ATS

KT-621, a potent, selective, oral STAT6 degrader, demonstrated comparable or superior activity to dupilumab in preclinical studies including an asthma model shared at the ATS Annual Meeting

JENA, Germany, May 21, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, announced data presented at the American Thoracic Society (ATS) 2024 International Conference that is being held from May 17-22, 2024 in San Diego.

Dupixent ® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ATS and published in NEJM NOTUS results confirm landmark data from the phase 3 BOREAS study and show Dupixent significantly reduced exacerbations by 34% and improved lung function, compared to placebo, in uncontrolled chronic obstructive pulmonary disease (COPD) with evidence of type 2 inflammation Data support the potential of Dupixent as the first new treatment approach in more than a decade and first-ever targeted therapy for COPD Paris and Tarrytown, N.Y. May 20, 2024.

The Phase IIa COURSE trial was conducted as a proof-of-concept study on individuals with moderate to very severe chronic obstructive pulmonary disease (COPD) across various levels of blood eosinophil counts (BEC) and regardless of emphysema, chronic bronchitis, or smoking status. The main findings indicated that treatment with AstraZeneca and Amgen's TEZSPIRE® (tezepelumab) resulted in a 17% decrease in the annual rate of moderate or severe COPD exacerbations compared to placebo.

New findings from the Phase 2a COURSE Trial show the impact of Tezspire on COPD exacerbations in patients with varying levels of eosinophils. Amgen and AstraZeneca released the results of the trial, which focused on individuals with moderate to very severe COPD, regardless of their baseline blood eosinophil counts, emphysema, chronic bronchitis, or smoking status.

Savara Inc., a biopharmaceutical company specializing in rare respiratory diseases, showcased a poster at the American Thoracic Society (ATS) 2024 International Conference in San Diego, CA. The Company's partner, Trillium Health LLC, also presented a poster on a new laboratory blood test for diagnosing aPAP. Summaries of the posters are provided below.

ATS Corporation (TSX: ATS) (NYSE: ATS) announced that their Chief Financial Officer, Ryan McLeod, will be attending Deutsche Bank's 15th Annual Global Industrials, Materials & Building Products Conference in New York, NY on June 5, 2024. ATS will be hosting a fireside chat at 9:20 a.m. (ET) during the event. A webcast link of the live event can be found on the Investor Relations site at https://investors.atsautomation.com/.

SAN DIEGO, May 16, 2024 (GLOBE NEWSWIRE) -- Event Details:          May 17–22, 2024 Location:         San Diego Convention Center (SDCC) | 111 Harbor Dr. San Diego, CA 92101                       Marriott Marquis San Diego Marina | 333 West Harbor Dr. San Diego, CA 92101 Study:     ATS will feature 26 abstracts supported by ResMed. See complete list below.

ATS Corporation (TSX and NYSE: ATS) announced its financial results for the three and twelve months ending March 31, 2024. In the fourth quarter, revenues grew by 8.3% to $791.5 million, while net income rose to $48.5 million from $29.6 million in the previous year. Basic earnings per share were 49 cents. All financial figures are in Canadian dollars unless specified otherwise.